![[CytoReason in NoCamels] As Israel Turns 74, Get To Know Some Of Its Most Innovative Companies](https://blog.ourcrowd.com/wp-content/uploads/2017/10/nocamels-NEW.jpg)
Israel is celebrating its 74th anniversary after a record-breaking year for its high-tech sector, with $5.6 billion raised in the first quarter of 2022 and over $25 billion raised through 2021. Read...
Read More![[CytoReason in Israel Hayom] Israel’s CytoReason, S. Korea’s Helixrus partner on machine learning for drug development](https://blog.ourcrowd.com/wp-content/uploads/2019/09/israel-hayom-test.jpg)
CytoReason, a developer of computational disease models for efficient drug discovery and development, has signed a commercial partnership with Helixrus, a Korean company focused on biological big data and multi-omics, the company announced Tuesday. The partnership will see Helixrus represent CytoReason’s unique artificial intelligence (AI) platform and professional services in the Korean market. Read...
Read More![[CytoReason on Proactive] Poolbeg Pharma plan to ‘unlock’ the influenza disease with CytoReason after signing AI deal](https://blog.ourcrowd.com/wp-content/uploads/2022/03/proactive_ytw.jpg)
Poolbeg Pharma’s Jeremy Skillington talks to Proactive London after signing a deal with CytoReason, a leading artificial intelligence (AI) to provide AI analysis of Poolbeg’s influenza disease progression data derived from human challenge study samples. Watch the video...
Read More![[CytoReason in Share Talk] Poolbeg Pharma PLC (AIM:POLB) Artificial Intelligence deal signed with CytoReason](https://blog.ourcrowd.com/wp-content/uploads/2022/03/share_talk_W.png)
24 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has signed a deal with CytoReason , a leading artificial intelligence (AI) company developing computational disease models for efficient drug discovery and development, to provide AI analysis of Poolbeg’s influenza disease progression data derived from human challenge study samples. Read...
Read More![[CytoReason in The Jerusalem Post] Israeli startup CytoReason collaborates with Pfizer on machine learning](https://blog.ourcrowd.com/wp-content/uploads/2017/10/Jerusalem-post.jpg)
Israeli start-up CytoReason – a leading developer of computational machine-learning models for drug development – announced the extension of its collaboration agreement with Pfizer, which began in 2019, on Thursday. Read...
Read More
